Brief: CohBar Provides Update On Phase 1A/1B Clinical Trial For CB4211 Under Development For NASH And Obesity
14/07/2021 14:41
July 14 (Reuters) - CohBar Inc CWBR.O :
* COHBAR PROVIDES UPDATE ON THE PHASE 1A/1B CLINICAL TRIAL
FOR
CB4211 UNDER DEVELOPMENT FOR NASH AND OBESITY
* COHBAR INC - CURRENTLY EXPECTS TO RELEASE TOPLINE DATA
FOR
PHASE 1A/1B CLINICAL STUDY OF CB4211 PRIOR TO LABOR DAY 2021
Source text for Eikon: ID:nGNX3FmBDF
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma